DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Di Leo A, Ciruelos E, Janni W. et al.
BELLE‑3: A phase III study of the panphosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.
ASCO Annual Meeting.
Chicago, Il: Abstract TPS626 2015
We do not assume any responsibility for the contents of the web pages of other providers.